Share-based Payment Arrangement, Expense of Twist Bioscience Corp from 30 Sep 2017 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Twist Bioscience Corp quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 30 Sep 2017 to 30 Sep 2025.
  • Twist Bioscience Corp Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2025 was $16,083,000, a 30% increase year-over-year.
  • Twist Bioscience Corp Share-based Payment Arrangement, Expense for the twelve months ending 30 Sep 2025 was $64,459,000, a 27% increase year-over-year.
  • Twist Bioscience Corp annual Share-based Payment Arrangement, Expense for 2025 was $64,459,000, a 27% increase from 2024.
  • Twist Bioscience Corp annual Share-based Payment Arrangement, Expense for 2024 was $50,925,000, a 68% increase from 2023.
  • Twist Bioscience Corp annual Share-based Payment Arrangement, Expense for 2023 was $30,278,000, a 62% decline from 2022.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

Twist Bioscience Corp Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $64,459,000 $16,083,000 +$3,736,000 +30% 01 Jul 2025 30 Sep 2025 10-K 17 Nov 2025 2025 FY
Q2 2025 $60,723,000 $16,057,000 +$2,323,000 +17% 01 Apr 2025 30 Jun 2025 10-Q 04 Aug 2025 2025 Q3
Q1 2025 $58,400,000 $20,328,000 +$6,504,000 +47% 01 Jan 2025 31 Mar 2025 10-Q 05 May 2025 2025 Q2
Q4 2024 $51,896,000 $11,991,000 +$971,000 +8.8% 01 Oct 2024 31 Dec 2024 10-Q 03 Feb 2025 2025 Q1
Q3 2024 $50,925,000 $12,347,000 +$601,000 +5.1% 01 Jul 2024 30 Sep 2024 10-K 17 Nov 2025 2025 FY
Q2 2024 $50,324,000 $13,734,000 +$3,136,000 +30% 01 Apr 2024 30 Jun 2024 10-Q 04 Aug 2025 2025 Q3
Q1 2024 $47,188,000 $13,824,000 +$3,565,000 +35% 01 Jan 2024 31 Mar 2024 10-Q 05 May 2025 2025 Q2
Q4 2023 $43,623,000 $11,020,000 +$13,345,000 01 Oct 2023 31 Dec 2023 10-Q 03 Feb 2025 2025 Q1
Q3 2023 $30,278,000 $11,746,000 -$7,023,000 -37% 01 Jul 2023 30 Sep 2023 10-K 17 Nov 2025 2025 FY
Q2 2023 $37,301,000 $10,598,000 -$9,261,000 -47% 01 Apr 2023 30 Jun 2023 10-Q 02 Aug 2024 2024 Q3
Q1 2023 $46,562,000 $10,259,000 -$12,078,000 -54% 01 Jan 2023 31 Mar 2023 10-Q 02 May 2024 2024 Q2
Q4 2022 $58,640,000 $2,325,000 -$20,393,000 -113% 01 Oct 2022 31 Dec 2022 10-Q 02 Feb 2024 2024 Q1
Q3 2022 $79,033,000 $18,769,000 +$9,521,000 +103% 01 Jul 2022 30 Sep 2022 10-K 18 Nov 2024 2024 FY
Q2 2022 $69,512,000 $19,859,000 +$10,683,000 +116% 01 Apr 2022 30 Jun 2022 10-Q 07 Aug 2023 2023 Q3
Q1 2022 $58,829,000 $22,337,000 +$10,785,000 +93% 01 Jan 2022 31 Mar 2022 10-Q 08 May 2023 2023 Q2
Q4 2021 $48,044,000 $18,068,000 +$11,046,000 +157% 01 Oct 2021 31 Dec 2021 10-Q 07 Feb 2023 2023 Q1
Q3 2021 $36,998,000 $9,248,000 +$4,118,000 +80% 01 Jul 2021 30 Sep 2021 10-K 21 Nov 2023 2023 FY
Q2 2021 $32,880,000 $9,176,000 +$5,104,000 +125% 01 Apr 2021 30 Jun 2021 10-Q 08 Aug 2022 2022 Q3
Q1 2021 $27,776,000 $11,552,000 +$7,355,000 +175% 01 Jan 2021 31 Mar 2021 10-Q 06 May 2022 2022 Q2
Q4 2020 $20,421,000 $7,022,000 +$3,325,000 +90% 01 Oct 2020 31 Dec 2020 10-Q 09 Feb 2022 2022 Q1
Q3 2020 $17,096,000 $5,130,000 +$1,767,000 +53% 01 Jul 2020 30 Sep 2020 10-K/A 05 Jun 2023 2022 FY
Q2 2020 $15,329,000 $4,072,000 +$1,040,000 +34% 01 Apr 2020 30 Jun 2020 10-Q 09 Aug 2021 2021 Q3
Q1 2020 $14,289,000 $4,197,000 +$1,286,000 +44% 01 Jan 2020 31 Mar 2020 10-Q 07 May 2021 2021 Q2
Q4 2019 $13,003,000 $3,697,000 +$1,833,000 +98% 01 Oct 2019 31 Dec 2019 10-Q 09 Feb 2021 2021 Q1
Q3 2019 $11,170,000 $3,363,000 +$2,277,000 +210% 01 Jul 2019 30 Sep 2019 10-K 23 Nov 2021 2021 FY
Q2 2019 $8,893,000 $3,032,000 +$2,429,000 +403% 01 Apr 2019 30 Jun 2019 10-Q 12 Aug 2020 2020 Q3
Q1 2019 $6,464,000 $2,911,000 +$2,175,000 +296% 01 Jan 2019 31 Mar 2019 10-Q 13 May 2020 2020 Q2
Q4 2018 $4,289,000 $1,864,000 +$1,328,000 +248% 01 Oct 2018 31 Dec 2018 10-Q 10 Feb 2020 2020 Q1
Q3 2018 $2,961,000 $1,086,000 01 Jul 2018 30 Sep 2018 10-K 27 Nov 2020 2020 FY
Q2 2018 $603,000 01 Apr 2018 30 Jun 2018 10-Q 09 Aug 2019 2019 Q3
Q1 2018 $736,000 01 Jan 2018 31 Mar 2018 10-Q 02 May 2019 2019 Q2
Q4 2017 $536,000 01 Oct 2017 31 Dec 2017 10-Q 11 Feb 2019 2019 Q1

Twist Bioscience Corp Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2025 $64,459,000 +$13,534,000 +27% 01 Oct 2024 30 Sep 2025 10-K 17 Nov 2025 2025 FY
2024 $50,925,000 +$20,647,000 +68% 01 Oct 2023 30 Sep 2024 10-K 17 Nov 2025 2025 FY
2023 $30,278,000 -$48,755,000 -62% 01 Oct 2022 30 Sep 2023 10-K 17 Nov 2025 2025 FY
2022 $79,033,000 +$42,035,000 +114% 01 Oct 2021 30 Sep 2022 10-K 18 Nov 2024 2024 FY
2021 $36,998,000 +$19,902,000 +116% 01 Oct 2020 30 Sep 2021 10-K 21 Nov 2023 2023 FY
2020 $17,096,000 +$5,926,000 +53% 01 Oct 2019 30 Sep 2020 10-K/A 05 Jun 2023 2022 FY
2019 $11,170,000 +$8,209,000 +277% 01 Oct 2018 30 Sep 2019 10-K 23 Nov 2021 2021 FY
2018 $2,961,000 +$1,070,000 +57% 01 Oct 2017 30 Sep 2018 10-K 27 Nov 2020 2020 FY
2017 $1,891,000 01 Oct 2016 30 Sep 2017 10-K 13 Dec 2019 2019 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.